Posted 5/6/2015 10:37 AM (GMT 0)
I understand that there is a survival benefit with Provenge, it continues to work in your system, and all the good things about it. But I don't understand why, if it's killing PC cells, can"t PSA be used as a marker to gauge treatment effectiveness?
Does this hold true for other immunotherapies for PC? Can they not use PSA as a marker as well?
Do other cancers that use immunotherapies have a similar dilemma where the primary marker(s) for their type of cancer can't be used to monitor effectiveness?
Thanks
Jerry